Impact of modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen on progression-free survival

被引：0
|
作者：
Lesnock, J. [1 ]
Chu, T. [1 ]
Richard, S. [2 ]
Kubenik, M. [1 ]
Krivak, T. [1 ]
Zorn, K. [1 ]
Sukumvanich, P. [1 ]
Kelley, J. [1 ]
Edwards, R. [1 ]
机构：
[1] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Magee Womens Hosp, Wexford, PA USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [41] Serum IL-33 level is a predictor of progression-free survival after chemotherapy
    Hu, Wenwei
    Wu, Chen
    Li, Xiaodong
    Zheng, Zhuojun
    Xie, Quanqin
    Deng, Xu
    Jiang, Jingting
    Wu, Changping
    ONCOTARGET, 2017, 8 (21) : 35116 - 35123
  • [42] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [43] Overall Survival: A Gold Standard in Search of a Surrogate The Value of Progression-Free Survival and Time to Progression as End Points of Drug Efficacy
    Zhuang, Sen H.
    Xiu, Liang
    Elsayed, Yusri A.
    CANCER JOURNAL, 2009, 15 (05): : 395 - 400
  • [44] Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer
    Qi, Yingwei
    Ziegler, Katie L. Allen
    Hillman, Shauna L.
    Redman, Mary W.
    Schild, Steven E.
    Gandara, David R.
    Adjei, Alex A.
    Mandrekar, Sumithra J.
    CANCER, 2012, 118 (21) : 5358 - 5365
  • [45] Toxicity of a modified outpatient regimen of intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in women with newly diagnosed ovarian cancer
    Ferguson, Sarah E.
    Black, Destin
    Chi, Dennis S.
    Sabbatini, Paul
    Konner, Jason
    Tew, William P.
    Hensley, Martee L.
    Barakat, Richard R.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : S17 - S18
  • [46] NSCLC: Pembrolizumab improves progression-free survival
    Simon, Annika
    PNEUMOLOGIE, 2023, 77 (04):
  • [47] Durvalumab boosts progression-free survival in NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (01): : E11 - E11
  • [48] Progression-free survival with regorafenib in gastric cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (08): : E323 - E323
  • [49] Osimertinib improves progression-free survival in NSCLC
    Pinion, Sheila
    LANCET RESPIRATORY MEDICINE, 2017, 5 (04): : 251 - 251
  • [50] Progression-Free Survival: Meaningful or Simply Measurable?
    Booth, Christopher M.
    Eisenhauer, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1030 - 1033
12345